The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly. It also assessed exenatide once weekly (exenatide extended-release for ...
Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...
If you have type 2 diabetes, your doctor may suggest Bydureon BCise (exenatide extended-release) as a treatment option. Along with other factors, you may have questions about possible side effects of ...
It is a once-weekly formulation of exenatide, the active ingredient in BYETTA ® (exenatide) injection, which has been available in the U.S. since June 2005 and is used in nearly 80 countries worldwide ...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...
In combination with diet and exercise, the diabetes drug exenatide helped nondiabetic, obese individuals lose over three times more weight than those receiving a placebo, or dummy treatment, for 6 ...
Investigational GLP-1 Treatment Improved Glucose Control with Just One Dose per Month SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback